Ravi, V., Brohl, A. S., Chawla, S. P., Attia, S., Riedel, R. F., Liebner, D. A., … Maki, R. G. (2018). Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS). In Journal of Clinical Oncology (Vol. 36, pp. e23570–e23570). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.e23570

Ravi, Vinod, Andrew Scott Brohl, Sant P. Chawla, Steven Attia, Richard F. Riedel, David A. Liebner, Katherine Anne Thornton, et al. “Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).” In Journal of Clinical Oncology, 36:e23570–e23570. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e23570.

Ravi V, Brohl AS, Chawla SP, Attia S, Riedel RF, Liebner DA, et al. Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. e23570–e23570.

Ravi, Vinod, et al. “Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. e23570–e23570. Crossref, doi:10.1200/jco.2018.36.15_suppl.e23570.

Ravi V, Brohl AS, Chawla SP, Attia S, Riedel RF, Liebner DA, Thornton KA, Basu Mallick A, Davis DW, Cervantes M, Liu W, Zhu K, Alvarez D, Theuer CP, Robinson SI, Penel N, Stacchiotti S, Tap WD, Jones RL, Maki RG. Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. e23570–e23570.